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Background. Falls and hip fractures are an increasing health threat to older people who often never return to independent living.
This study examines the management of bone health in an acute care setting following a hip fracture in patients over age 65.
Methods. Retrospective chart review of all patients admitted to a tertiary health facility who suﬀered a recent hip fracture. Results.
420 charts of patients admitted over the course of a year (May 1, 2007–April 31, 2008) were reviewed. Thirty-seven percent of
patients were supplemented with calcium on discharge, and 36% were supplemented with vitamin D on discharge. Thirty-one
percentweredischargedonabisphosphonate.Conclusion.Asigniﬁcantcaregapstillexistsinhowosteoporosisisaddresseddespite
guidelines on optimal management. A call to action is required by use of multifaceted approaches to bridge the gap, ensuring that
fracture risk is minimized for the aging population.
1.Introduction
Osteoporosis is a major threat to the well being of our
agingpopulation,bothinCanadaandworldwide.InCanada,
approximately 1 in 4 women and one in 8 men suﬀer from
this condition [1]. A woman reaching the age of 50 has a
40% life time risk of a fracture (at the wrist, vertebra or hip)
[2]. Up to 95% of fractures in patents older than 75 who are
hospitalized for a fracture, and 80–90% in those 60–74 years
of age, can be attributed to osteoporosis [3]. By 2050, the
worldwide incidence of hip fractures is projected to increase
by 310% in men and 240% in women [4].
Among osteoporotic fractures, those at the hip are
associated with the highest morbidity and mortality, with
about20%dyingand50%becominginstitutionalizedwithin
the ﬁrst year of the fracture [5]. Those who have a hip
fracture are at a greater risk of a second osteoporosis-related
fracture [6]. Of all recurrent fractures occurring within 2
years after a fracture, 60% occurred during the ﬁrst year and
40% during the second year. The absolute risk to develop
an incident clinical fracture within 2 years after any clinical
fracture is 10.8% [7].
The primary goal of therapy after a fragility fracture (a
fracture resulting from mechanical forces that would not
ordinarily cause fracture, such as a fall from standing height)
should be to prevent future fractures, which is accomplished
byslowingorstopping boneloss,maintaining bonestrength,
and minimizing or eliminating factors that contribute to
fractures (e.g., falls).
Inadequate mean baseline calcium intake was found in
85% of subjects in six major osteoporosis trials [8]. As
well, more than half of a sample of 1536 women with
postmenopausal osteoporosis had serum 25(OH) D levels
below those associated with secondary hyperparathyroidism
[9]. A Finnish study found that post hip-fracture death can2 Journal of Osteoporosis
be decreased by 36% in females and 43% in males at 3 years
by treatment with calcium and vitamin D after fracture.
However, in women taking the regimen of a bisphosphonate
with calcium and vitamin D, the mortality at 3 years was
decreased by 43% [10]. What is alarming is the fact that
evenlesspersistencewithtreatmentisseenovertime.Rabeda
et al. reported that for 23,146 patients in Belgium, who
had sustained hip fracture, only 6% were discharged on a
bisphosphonate [4]. At 6 months, 2.6% were taking their
bisphosphonate and at 1 year, 3.6%.
At this time, bisphosphonates are the accepted ﬁrst-line
therapy in fracture prevention for both men and post-
menopausal women, together with supplementation of
vitamin D and calcium, although new treatments are on
the horizon [4]. The Canadian Clinical Practice Guidelines
(CPGs) were initially published in 2002 and updated in 2006
andmorerecentlyin2010,http://www.cmaj.ca/cgi/rapidpdf/
cmaj.100771v1?ijkey=460251aca11ba674e2b5b01f8bbe0f1b0
80b75d8&keytype2=tf ipsecsha [11]. These guidelines clear-
ly outline risk factor assessment, investigations, and man-
agement of fragility fractures [12, 13]. In the most recent
update, they clearly state that treatment of osteoporosis is
justiﬁed regardless of the BMD level in patients who have
already sustained a fragility fracture and are on prolonged
glucocorticoid treatment (more than 3 months at 7.5mg or
more of prednisone equivalent).
A systematic review concluded that the median rate of
osteoporosis investigation in patients who had sustained a
fragility fracture was 11% (0.5–32%), and fewer than 10%
of patients were treated with antiresorptive therapy [14]. In a
review of 298 patients with distal radius fracture, only 21.3%
had a DXA scan ordered to investigate for osteoporosis [15].
The literature is emerging on the barriers to care. Several
patient-related barriers of initiation of eﬀective osteoporosis
management have been identiﬁed: age, dementia, medical
co-morbidities, polypharmacy, lack of adherence to treat-
ment,post-operative delirium, languagebarriers, inadequate
support, lack of access to care by a primary care physician,
and social economic status [16].
Physician and system-related barriers have been
acknowledged including lack of time, cost of resources for
diagnosis, lack of knowledge and concernabout osteoporosis
treatment, and lack of clarity whose responsibility is it to
initiate and promote osteoporosis care. Furthermore,
inadequacy of communication between orthopedics and the
family physician, insuﬃcient means of transportation for
patient followups, and uncertainties in applying disease-
speciﬁc guidelines to older patients with comorbidities
contribute to these barriers [17]. One study reports that
most orthopedic surgeons believe that while they are
primarily responsible for the surgical care of their hip
fracture patients, the management of osteoporosis is
considered the responsibility of the primary care physician
[18].
In a previous study performed in 1999-2000 at The
Ottawa Hospital, Civic Campus, a tertiary care centre, we
demonstrated a similar care gap as in published literature,
in the management of osteoporosis in older hip fracture
patients [19]. In this study of 147 patients over 65 years
Table 1: Demographics (n = 420).
Patient characteristics
Female N(%) 310 (74%)
Age
Mean (Std) 83.1 (7.5)
Median 83
Range 66–103
Average length of stay (days)
Mean (Std) 21.1 (33.3)
Median 11
Range 0–431
of age, admitted with a hip fracture, management included
only 14% being supplemented with vitamin D, 15.6% were
supplemented with calcium, and 4.8% of the total sample
were discharged on a bisphosphonate (Figure 3).
2.Objective
We report the results of this current follow-up study to
evaluate how we are doing 5 years after the initial 2002CPG
were made available to the Canadian health care system, as
compared to the initial study in 1999, and on the heels of the
recent updated 2010CPG. Strategies on how to bridge the
gap in the most vulnerable population, those who suﬀered
a hip fracture, in light of the recent 2010 osteoporosis
guidelines, will be presented.
3. Methods
Retrospective chart review was conducted of all the hip frac-
ture patients at The Ottawa Hospital (now combined Civic
and General campuses) using a standardized questionnaire.
Research ethics approval was obtained from The Ottawa
Research Ethics Board.
4. Results
4.1. Demographics. The charts of 420 patients over the age
of 65 years, admitted over the course of one year (May
1, 2007–April 30, 2008), were reviewed (Table 1). Of the
patients, 74% were female and the mean age was 83 years.
The average length of stay was 21 days with 82% being
discharged from an orthopedic ward, further 6% from the
Geriatric Assessment Unit (GAU) (Figure 1). Data on co-
morbidities was available only on 147 patients, with the
most frequent being hypertension (58%), previous history
of falls (57%), previous diagnosis of osteoporosis (28%),
cardiovascular disease (27%), osteoarthritis (23%), previous
fracture (22%), and cognitive impairment (28%).
4.2. Patient Living Arrangements on Admission and Discharge.
Of the 420 charts reviewed, the living arrangements upon
admission were: 72.5% patients being admitted from home,
23.6% from nursing home, and 3.9% from other settings.
However, the discharge locations were quite diﬀerent with
only 15.8% patients discharged going home, 32.7% to a
nursing home, 31.2% to a rehabilitation facility, and 20.3%Journal of Osteoporosis 3
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Figure 1: Ward location on discharge.
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Figure 2: Patient living arrangement at admission and discharge.
to other settings (e.g., boarding home, other hospital)
(Figure 2).
4.3.UseofCalciumSupplementation.Ondischarge(Figure 3),
37% of patients were started on calcium supplementation,
with 17% already being on these supplements prior to
admission, for a total of new supplementation of calcium of
20%. Sixty-one percent were not supplemented with calcium
on discharge. In 2% the discharge treatment did not include
calcium, even though they were on it prior to admission.
4.4. Use of Vitamin D Supplementation. On discharge
(Figure 3), 36% of patients were started on vitamin D
supplementation, with 14% of these patients being on
vitamin D at time of admission, for a total of 21% new
supplementation of vitamin D. Sixty-three percent were
not recommended to start vitamin D, and 1% were not
continued on vitamin D, even though it was listed in their
admission medications.
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Figure 3: Medications at admission and discharge (as compared to
1999-2000 Study).
4.5. Use of Bisphosphonates. On discharge (Figure 3), 31%
of patients were started on a bisphosphonate (either alen-
dronate 17%, risedronate 10%, or etidronate 4%), with 10%
alreadybeingonabisphosphonatepriortoadmission,giving
a 21% rate of new prescribing. Sixty eight percent were not
on a bisphosphonate on discharge. In 1% bisphosphonate
was discontinued on discharge.
4.6. Management on GAU Unit. A further subgroup analysis
of the smaller sample (n = 26) of patients discharged
from the GAU was performed (Figure 4), demonstrating
that 100% of patients were discharged on calcium (19%
were on calcium preadmission) and vitamin D (12% were
on vitamin D on admission), and 77% were prescribed a
bisphosphonate. Of these, 15% were on a bisphosphonate
before admission, for an increase in prescribing of 62% of
bisphosphonate treatment.
4.7. DXA Scan. On discharge, 7% of all patients had a DXA
scan ordered. Of the GAU subgroup analysis (n = 26), 58%
were prescribed a DXA scan.
5. Discussion
Despite several years since the publication of the original
Canadian practice guidelines on osteoporosis management,
in addition to other international guidelines, we are still
struggling with managing this challenging health care issue.
Osteoporosis management may not be viewed as a high
priority during in-hospital care, leaving this to “outpatient
investigation and management by primary care physicians,”
or to a “consultant service.” There seems to be a general
lack of awareness and ownership of the problem [20]. This
is evident from our study as well, as treatment rates were
generally greater on the GAU although a major limitation is
the comparably smaller sample (344 versus 26). Following
the initial study [19], several interventions were instituted
on the GAU, such as staﬀ education, osteoporosis discharge
check list, and providing a patient education binder. This4 Journal of Osteoporosis
resulted in raising general awareness and a culture of
managing osteoporosis and fracture risk.
A limitation of our study is that it is a retrospective
chart review, so we were unable to explore the reasons why
treatment was not initiated and therefore can only speculate.
While 100% of patients on the GAU were discharged on
calcium and vitamin D, only 77% were discharged on
a bisphosphonate with 62% being new prescriptions. For
those who were not treated, some of the barriers described
above could have also played a role in lower adherence to
guidelines.
Our study was also limited by lack of follow-up data
to verify if treatment was commenced eventually by family
physicians for those who left hospital on no treatment, and if
the persistence was maintained. Previous studies with family
physicians demonstrate that they are often unclear about
the rationale for therapy and do not feel that they have the
adequate resources, information and time to deal with this
issue. In a small trial in a community-based setting after
hip fracture, less than one-third of patients randomized to
the control group received adequate care (including bone
density measurement, bisphosphonate, vitamin D, calcium,
or exercise prescription) despite being admitted to a tertiary
hospital and having follow up with their family physician
[20]. This discrepancy in care delivery contributes to the
continued care gap in fracture prevention, especially for
those patients admitted to hospital, who are often older, frail
individuals with many co morbidities, often suﬀering from
prolonged immobility, and barriers to seeking care following
discharge, as outlined above.
Our data also suggests that the rate of DXA scans ordered
on admission was low in the overall sample, although higher
on the GAU (58%). One approach to improve the adherence
with therapy could involve ensuring that the result of the
DXA report is sent to the family physician for follow-up.
Patients admitted to hospital with fragility fractures
could be routinely supplemented with calcium and vitamin
D, given the prevalence of inadequate levels of calcium [8]
andvitaminD[9]reportedintheliterature.Thecurrenttotal
daily recommendations are now for 1200mg of elemental
calcium and 800–2000IU of vitamin D [11]. Educating
patients as well is pivotal in managing osteoporosis and
pamphlets on the subject matter with instructions, given on
discharge, may help to bridge the current care gap. Gardner
etal.[21]showedanimprovementinosteoporosis treatment
with their intervention group that went through discussion
during hospitalization about osteoporosis, diagnosis, treat-
ment, and series of questions to discuss further with their
family physician. At 6 weeks after discharge from hospital,
this intervention group was found to have osteoporosis
addressed by family physician in 42% versus 19% in the
regular treatment group. In another study, care pathways
have been explored in a London, Ontario study for patients
with hip fracture. The result showed improvement (13.5%
versus 72%) with calcium and vitamin D treatment [22].
The role of Osteoporosis Nurse Specialists has been
recognized to play an important role in identifying patients
at risk [17]. They can assist in liaison of the multidisciplinary
teams with staﬀ emergency physicians, orthopedic surgeons,
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Figure 4: Medication at admission, discharge, and new prescrip-
tions in GAU Group.
rehabilitation specialists, and primary care physicians. For
example, Bogoch et al. [23] have championed a program
for osteoporosis education, investigation and treatment in
349 patients (both inpatients and outpatients with fragility
fracture in Toronto, Ontario, Canada). They were able to
achieve a 96% rate of appropriate attention for osteoporosis
in their Osteoporosis Exemplary Care program. This is an
example of a coordinated program that has been rolled out
to some regions of the province, but it requires resources
and attention of local health authorities. Fracture clinics
are beginning to utilize these resources, but they are often
reserved for ambulatory outpatients.
In Ottawa, the Ontario Osteoporosis Screening program
http://www.osteostrategy.on.ca/ has been active since 2007
and is run out of the fracture clinics. Unfortunately, hip
fracture patients who are often older may not be accessing
these services for the reason and barriers outlined above.
Although bisphosphonates are recognized as ﬁrst-line
therapy, concerns have been raised about potential side
eﬀects such as osteonecrosis of the jaw and proximal
femur fractures. The overall risk is extremely low, especially
given the grim prognosis of a hip fracture. Black et al.
demonstrated the risk of proximal femur fractures, (as bone
turnover may be decreased with long-term bisphosphonate
therapy), to be 2.3 per 10,000 patient years [24]. The
National Osteoporosis Foundation (NOF), in its clinical
update online of July 2008, stated, “Results suggest that
for most women, taking a 5-year drug holiday” after being
on alendronate for 5 years does not increase fracture risk
and might be advantageous [24]. Osteonecrosis of the jaw,
which mainly aﬀects those with malignancies being treated
with intravenous forms of bisphosphonates, is estimated
to have an incidence of 0.7 per 100,000 patient years
[25]. Notwithstanding these concerns, treatment must be
individualized.
The time of hospital admission is a prime opportunity
to bridge this care gap, and systemic solutions need to be
institutedtoensurethatosteoporosisisaddressedfollowinga
fragility fracture. Haynes et al. have proposed a checklist, forJournal of Osteoporosis 5
Table 2: Top ten suggested recommendations for all hip fracture patients over age 65.
(1) Supplement to total (dietary and prescribed) elemental calcium 1200mg daily (as average daily dietary calcium intake is around
600mg, supplement with extra 600mg, unless high dietary intake history)
(2) Supplement with vitamin D 800–2000I.U. daily
(3) Consider ﬁrst-line treatment with bisphosphonate-alendronate, risedronate, or i.v. zoledronic acid
( 4 )N on e e df o rD X As c a nto initiate treatment, consider baseline DXA scan to assess bone density to follow response to treatment
(5) Assess and minimize fall risk and review all contributing risk factors
(6) Hip protectors if compliance can be ascertained (supervision, long term care setting)
(7) Patient and family education on osteoporosis, risk factors, importance of treatment to assure patient understanding, and improved
compliance
(8) Encourage exercise—Tai Chi for balance and weight bearing if possible
(9) Develop specialized follow-up fracture clinics and orthogeriatric collaboration services for older hip fracture adults
(10) Followup DXA scan at the same location to asses bone density 1–3 years after the initiation of treatment to ensure compliance
and response
use in surgery as a safety net to improve team communica-
tionandconsistencyofcare[26].Perhapsthiscanbeadapted
in other areas of our health care, including for older patients
whosuﬀeredhipfractures.Table 2 listsrecommendationsfor
older hip fracture patients based on the 2010 guidelines.
6. Conclusion
Future research must focus on treatment evaluation and
continuous quality improvement to achieve most eﬀective
measures for the implementation of the guidelines’ recom-
mendations and for improved compliance.
We require a call to action for a multifaceted, multidi-
mensional model of care, to help address this care gap in
our aging fracture susceptible population, at every point of
contact, as many older patients may not have a primary
care physician to follow up. Hopefully the next decade will
see a widespread excellence of improved care models, as
knowledge is gained, and other treatment options emerge.
7. Key Points
(1) Osteoporosis care gap continues in older patients with
hip fractures: osteoporosis is underrecognized and under-
treated in this population.
(2) Management should be instituted at time of hospital-
ization, including starting calcium, vitamin D, and possibly
a bisphosphonate, with treatment individualized for each
older person given their comorbidities.
(3) Multidimensional interventions need to be implemented
in addressing this health care threat to our aging population;
for example, Osteoporosis Nurse Specialist led screening,
follow up clinics, fall prevention clinics, exercise, and
nutritional evaluation.
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